Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 6

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 6
---
 extent of surgery needed to remove cancers and improve quality of life,
and (4) leverage our next generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T
therapies and other personalized medicines targeting cancers.

In
addition to private and public investment into our candidate therapeutic technology, we have also competed for non-dilutive funding from
the NIH to support our lead sensitizer and to explore development of complimentary diagnostic products. To date, we have completed three
SBIR contracts awarded to Shuttle Pharma by the NIH to:

7

    ●
    Develop
    IPdR as a radiation sensitizer. This funding provided partial support for the Phase I clinical trial of Ropidoxuridine and RT.

    ●
    Develop
    prostate cancer cell cultures from African-American men, with donor matched normal prostate cells, establishing 50 pairs for accelerating
    research to reduce prostate cancer health disparities in African-American men. This project was funded under “Moonshot”
    designation. Shuttle Pharma is eligible to apply for additional SBIR (Phase IIb) funding to commercialize these cells for research
    purposes. Currently, cells from African-American patients are distributed, on request, to investigators who are conducting health
    disparities research. We plan to test new small molecules using these cellular reagents for health disparities screening.

    ●
    Develop
    a predictive biomarker for determining outcomes for prostate cancer patients following treatment with RT. This SBIR-funded project
    for blood test (PC-RAD Test) discovery and analytical validation were completed on March 15, 2022, and Shuttle Pharma intends to
    perform a clinical validation study. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker
    test from Georgetown University and will seek additional investment from the public market to advance clinical development through
    its Shuttle Diagnostics entity.

All
three SBIR funded projects have been completed. The Company is eligible to apply for SBIR Phase IIb funding to advance the “Moonshot”
health disparities or the predictive biomarker project. The NIH SBIR program is designed to encourage small businesses to engage in Federal
Research/Research and Development (“R/R&D”) that has the potential for commercialization.

Shuttle
Pharma’s scientists have also developed collaborations to invent intellectual properties for prostate cancer theranostics. From
a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for diagnosis and therapy of prostate cancer.
In a discovery project to develop a